Rxcurve
HCPCS J9029 · per PER THERAPEUTIC DOSE

Instill adstiladrin, tx dose

Products billed under this code include Adstiladrin.

Payment limit per PER THERAPEUTIC DOSE, by effective quarter, 2Q24 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.

Products billed under J9029

From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.

ProductLabelerNDCUnits / pkgLimit / pkg
Adstiladrin Ferring Pharmaceuticals Inc. 55566-1050-01 1 $65,200.563

Every quarter

QuarterPayment limitChangeBilling unitDescriptionSource file
4Q26 $65,200.563 +$868.949 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted September 17, 2026
3Q26 $64,331.614 +$49.315 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted September 15, 2026
2Q26 $64,282.299 +$7.508 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted September 15, 2026
1Q26 $64,274.791 +$932.509 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted September 15, 2026
4Q25 $63,342.282 −$88.771 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted September 8, 2026
3Q25 $63,431.053 +$195.446 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted March 10, 2026
2Q25 $63,235.607 −$166.436 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted March 10, 2026
1Q25 $63,402.043 +$47.27 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted December 19, 2025
4Q24 $63,354.773 −$144.56 PER THERAPEUTIC DOSE Instill adstiladrin, tx dose v1, posted June 11, 2025
3Q24 $63,499.333 −$6.067 PER THERAPEUTIC DOSE Inj, adstiladrin, per tx dos v1, posted June 11, 2025
2Q24 $63,505.40 – PER THERAPEUTIC DOSE Inj, adstiladrin, per tx dos v1, posted March 11, 2025

“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.

CMS source files